Part of these data were presented in abstract form at the 25th Annual Meeting of the American Society of Bone and Mineral Research, Minneapolis, Minnesota, USA, September 19-23, 2003.
RANKL Regulates Fas Expression and Fas-Mediated Apoptosis in Osteoclasts†
Article first published online: 25 OCT 2004
Copyright © 2005 ASBMR
Journal of Bone and Mineral Research
Volume 20, Issue 1, pages 107–116, January 2005
How to Cite
Wu, X., Pan, G., McKenna, M. A., Zayzafoon, M., Xiong, W.-C. and McDonald, J. M. (2005), RANKL Regulates Fas Expression and Fas-Mediated Apoptosis in Osteoclasts. J Bone Miner Res, 20: 107–116. doi: 10.1359/JBMR.041022
The authors have no conflict of interest.
- Issue published online: 4 DEC 2009
- Article first published online: 25 OCT 2004
- Manuscript Accepted: 12 AUG 2004
- Manuscript Revised: 6 JUL 2004
- Manuscript Received: 31 MAR 2004
Osteoclast apoptosis is an influential determinant of osteoclast bone-resorbing activity. RANKL, a critical factor for osteoclastogenesis, is also important in osteoclast survival. However, the mechanisms by which RANKL prevents osteoclast apoptosis remain largely unknown.
Introduction: Fas, a death receptor, mediates apoptosis in multiple types of cells including osteoclasts. Here we report that RANKL acts as a survival factor in osteoclasts by downregulating Fas-mediated apoptosis and Fas expression in mature osteoclasts.
Materials and Methods: RAW264.7 and mouse bone marrow macrophage/monocyte progenitors and progenitor-derived osteoclasts, in the presence of various concentrations of RANKL, were used in this study. Western blotting, semiquantitative RT-PCR, flow cytometry, nuclear staining, and a fluorescent caspase-3 activity assay were used to assess the effect of RANKL on Fas expression and Fas-mediated apoptosis. The involvement of NF-κB in the regulation of Fas by RANKL was analyzed by luciferase assay and EMSA.
Results: Mature osteoclasts generated in the presence of a high concentration of RANKL (3.33 nM) failed to respond to Fas-induced apoptosis. The lack of responsiveness in mature osteoclasts is caused by the low level of Fas expression, as detected by both semiquantitative PCR and Western blotting. Fas protein and mRNA expression are inhibited by RANKL in concentration-dependent manners. The downregulation of Fas expression by RANKL is not because of modulation of the stability of Fas protein or mRNA. The regulation of Fas expression by RANKL is biphasic. During the early stage of osteoclastogenesis (1 day) when Fas is expressed at a very low level, RANKL upregulates Fas promoter activity by 2.4 ± 0.1-fold in a concentration-dependent manner and increases Fas mRNA and protein. This event correlates with regulation of the binding activity of NF-κB to the Fas promoter by RANKL, as detected by EMSA. In osteoclast precursors, the induction of Fas promoter activity by RANKL was dramatically reduced when NF-κB binding sites on the Fas promoter were mutated.
Conclusion: RANKL upregulates Fas expression in osteoclast progenitors through NF-κB, making osteoclasts targets of Fas-stimulated apoptosis. In differentiated mature osteoclasts, RANKL reduces the levels of Fas expression and Fas-mediated apoptosis, acting as a survival factor.